Eflapegrastim: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Eflapegrastim. Educational only — not medical advice.
Labeled uses
Rolvedon is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. Limitations of Use Rolvedon is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Source: FDA labeling via NIH DailyMed (set 2dc62c46…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.